{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:53:28Z","timestamp":1760576008772,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.clon.2013.01.008","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T00:51:03Z","timestamp":1362444663000},"page":"290-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of Metastatic Bone Disease in the Elderly with Bisphosphonates and\u00a0Receptor Activator of NF-kB Ligand Inhibitors: Effectiveness and Safety"],"prefix":"10.1016","volume":"25","author":[{"given":"Vassilios","family":"Vassiliou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2013.01.008_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0889-8588(05)70275-6","article-title":"Aging and cancer in America. Demographic and epidemiologic perspectives","volume":"14","author":"Yancik","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clon.2013.01.008_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.critrevonc.2008.07.008","article-title":"Are bisphosphonates the suitable anticancer drugs for the elderly?","volume":"69","author":"Santini","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clon.2013.01.008_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000080996","article-title":"Safety of long-term administration of bisphosphonates in elderly cancer patients","volume":"67","author":"Tralongo","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.clon.2013.01.008_bib4","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2013.01.008_bib5","first-page":"521","article-title":"Renal toxicities of chemotherapy","volume":"19","author":"Patterson","year":"1992","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib6","first-page":"408","article-title":"Bisphosphonates for malignancy-related bone disease: current status, future developments","volume":"14","author":"Body","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clon.2013.01.008_bib7","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2013.01.008_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003474.pub2","article-title":"Bisphosphonates for breast cancer","volume":"3","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clon.2013.01.008_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003474.pub3","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clon.2013.01.008_bib10","unstructured":"Zometa (zoledronic acid). Summary of product characteristics. Novartis Pharma, April 2005."},{"key":"10.1016\/j.clon.2013.01.008_bib11","unstructured":"Body JJ. Safety and tolerability of bisphosphonates in elderly: objective data. Presented at the 6th Meeting of ISGO\/SIOG, Geneva, 2005."},{"issue":"Suppl. 14s","key":"10.1016\/j.clon.2013.01.008_bib12","article-title":"Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics","volume":"22","author":"Mazj","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib13","first-page":"755","article-title":"Impact of zoledronic acid (Zol) on renal function in patients (pts) with cancer: is constant monitoring necessary","volume":"22","author":"Kloth","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.clon.2013.01.008_bib15","first-page":"745","article-title":"Renal dysfunction with IV bisphosphonates in patients with metastatic breast cancer","volume":"22","author":"Stein","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib16","first-page":"738","article-title":"Significant deterioration in renal function with the new bisphosphonate, zoledronic acid","volume":"22","author":"Jonhson","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib17","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2006.12.006","article-title":"International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients","volume":"43","author":"Body","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2013.01.008_bib18","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate, Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib19","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib20","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2013.01.008_bib21","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semnephrol.2003.08.015","article-title":"Hypercalcemia of malignancy","volume":"24","author":"Body","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.clon.2013.01.008_bib23","unstructured":"Aredia (pamidronate). SmPC. Novartis Pharmaceutical UK. 4 January 2005."},{"key":"10.1016\/j.clon.2013.01.008_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2013.01.008_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A\u00a0randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clon.2013.01.008_bib27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clon.2013.01.008_bib28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00002018-200326090-00005","article-title":"Extended safety profile of oral clodronate after long term use in primary breast cancer patients","volume":"26","author":"Atula","year":"2003","journal-title":"Drug Safety"},{"key":"10.1016\/j.clon.2013.01.008_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10585-007-9056-z","article-title":"Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a co revelation between the clinical status of patients and the type of bone metastases?","volume":"24","author":"Vassiliou","year":"2007","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clon.2013.01.008_bib30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.clon.2009.07.011","article-title":"Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy: interactions and effectiveness","volume":"21","author":"Vassiliou","year":"2009","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib31","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2013.01.008_bib32","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib33","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group","volume":"14","author":"Conte","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib34","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib35","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.clon.2013.01.008_bib36","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2013.01.008_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(11)70106-X","article-title":"A\u00a0multicentre trial of ibandronate compared to single dose radiotherapy for localized metastatic bone pain in prostate cancer (RIB)","author":"Hoskin","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2013.01.008_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijrobp.2006.08.022","article-title":"Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment","volume":"67","author":"Vassiliou","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2013.01.008_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10585-007-9066-x","article-title":"A\u00a0novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate","volume":"24","author":"Vassiliou","year":"2007","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clon.2013.01.008_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0360-3016(03)00525-X","volume":"57","author":"Kouloulias","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2013.01.008_bib41","first-page":"441","article-title":"Osteonecrosis of the jaw in a patient treated with ibandronate","volume":"13","author":"Vomvas","year":"2008","journal-title":"J\u00a0Buon"},{"key":"10.1016\/j.clon.2013.01.008_bib42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaw in cancer patients","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clon.2013.01.008_bib43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00066-010-2066-9","article-title":"Osteonecrosis of the jaws","volume":"186","author":"Vassiliou","year":"2010","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clon.2013.01.008_bib44","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib45","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pros.20678","article-title":"RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes","volume":"68","author":"Armstrong","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.clon.2013.01.008_bib47","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2008.10.047","article-title":"Inhibition of bone resorption and growth of breast cancer in the bone microenvironment","volume":"44","author":"Buijs","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.clon.2013.01.008_bib48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","article-title":"Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis","volume":"25","author":"Canon","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clon.2013.01.008_bib49","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1359\/jbmr.060706","article-title":"Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration","volume":"21","author":"Feeley","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.clon.2013.01.008_bib50","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clon.2013.01.008_bib51","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2006.09.016","article-title":"Inhibition of bone resorption, rather than direct cytotoxicity, mediates the antitumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis","volume":"40","author":"Zheng","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.clon.2013.01.008_bib52","unstructured":"US Food and Drug Administration. Xgeva BLA 125320\/7 Approval Letter 2010."},{"key":"10.1016\/j.clon.2013.01.008_bib53","unstructured":"European Medicines Agency. Xgeva. In: EPAR Summary for the Public. London: European Medicines Agency, 2012."},{"key":"10.1016\/j.clon.2013.01.008_bib54","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bone.2010.03.001","article-title":"Inhibition of RANKL increases the antitumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis","volume":"46","author":"Canon","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.clon.2013.01.008_bib55","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/cbt.9.7.11266","article-title":"Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L\/TRAIL\/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis","volume":"9","author":"Holland","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clon.2013.01.008_bib56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2013.01.008_bib57","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib58","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib59","first-page":"38","article-title":"Benefits of vitamin D supplementation","volume":"14","author":"Kauffman","year":"2009","journal-title":"J\u00a0Am Phys Surg"},{"key":"10.1016\/j.clon.2013.01.008_bib60","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1200\/JCO.2010.33.9150","article-title":"Denosumab for bone metastases from breast cancer: a new therapy option?","volume":"29","author":"Aapro","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib61","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(11)60100-1","article-title":"Unraveling the role of denosumab in prostate cancer","volume":"377","author":"Aragon-Chillag","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2013.01.008_bib62","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.2010.33.5596","article-title":"Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value","volume":"29","author":"West","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.01.008_bib63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1586\/erp.12.31","article-title":"Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer","volume":"12","author":"Carter","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clon.2013.01.008_bib64","first-page":"89","article-title":"Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors","volume":"6","author":"Brown-Glaberman","year":"2012","journal-title":"Biologics"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:38:53Z","timestamp":1760542733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655513000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0936655513000940"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2013.01.008","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Metastatic Bone Disease in the Elderly with Bisphosphonates and\u00a0Receptor Activator of NF-kB Ligand Inhibitors: Effectiveness and Safety","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2013.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}